{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:19:15Z","timestamp":1792783155899,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ankara University Scientific Research Projects Coordination Unit","award":["Project number: TDS-2022-2401"],"award-info":[{"award-number":["Project number: TDS-2022-2401"]}],"id":[{"id":"https:\/\/ror.org\/01wntqw50","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05649-0","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:18:24Z","timestamp":1784539104000},"page":"4181-4196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["miR-770-5p regulates KDM5B and links its nuclear localization to HER2 signaling in trastuzumab-resistant breast cancer"],"prefix":"10.1007","volume":"481","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-3702","authenticated-orcid":false,"given":"Senem","family":"Noyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4751-2372","authenticated-orcid":false,"given":"Hakan","family":"Gurdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5393-6115","authenticated-orcid":false,"given":"Alp","family":"Can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4320-5685","authenticated-orcid":false,"given":"Bala","family":"Gur Dedeoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"5649_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184522","author":"M Tapia","year":"2023","unstructured":"Tapia M, Hernando C, Mart\u00ednez MT et al (2023) Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15184522","journal-title":"Cancers (Basel)"},{"key":"5649_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E (2023) Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 22:101\u2013126. https:\/\/doi.org\/10.1038\/s41573-022-00579-0","journal-title":"Nat Rev Drug Discov"},{"key":"5649_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.breast.2022.10.016","volume":"66","author":"E Rassy","year":"2022","unstructured":"Rassy E, Rached L, Pistilli B (2022) Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer. Breast 66:217\u2013226. https:\/\/doi.org\/10.1016\/j.breast.2022.10.016","journal-title":"Breast"},{"key":"5649_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5306\/wjco.v8.i2.120","volume":"8","author":"V Masoud","year":"2017","unstructured":"Masoud V, Pag\u00e8s G (2017) Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol 8:120\u2013134. https:\/\/doi.org\/10.5306\/wjco.v8.i2.120","journal-title":"World J Clin Oncol"},{"issue":"2","key":"5649_CR5","doi-asserted-by":"publisher","first-page":"R46","DOI":"10.1186\/bcr2868","volume":"13","author":"M Barok","year":"2011","unstructured":"Barok M, Tanner M, K\u00f6ninki K, Isola J (2011) Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 13:R46. https:\/\/doi.org\/10.1186\/bcr2868","journal-title":"Breast Cancer Res"},{"key":"5649_CR6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719\u2013726. https:\/\/doi.org\/10.1200\/JCO.2002.20.3.719","journal-title":"J Clin Oncol"},{"key":"5649_CR7","first-page":"1045","volume":"10","author":"J Kreutzfeldt","year":"2020","unstructured":"Kreutzfeldt J, Rozeboom B, Dey N, De P (2020) The trastuzumab era: current and upcoming targeted HER2\u2009+\u2009breast cancer therapies. Am J Cancer Res 10:1045\u20131067","journal-title":"Am J Cancer Res"},{"key":"5649_CR8","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","volume":"32","author":"EA Perez","year":"2014","unstructured":"Perez EA, Romond EH, Suman VJ et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32:3744\u20133752. https:\/\/doi.org\/10.1200\/JCO.2014.55.5730","journal-title":"J Clin Oncol"},{"key":"5649_CR9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","volume":"15","author":"L Gianni","year":"2014","unstructured":"Gianni L, Eiermann W, Semiglazov V et al (2014) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 15:640\u2013647. https:\/\/doi.org\/10.1016\/S1470-2045(14)70080-4","journal-title":"Lancet Oncol"},{"key":"5649_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02039-0","volume":"9","author":"W Dai","year":"2024","unstructured":"Dai W, Qiao X, Fang Y et al (2024) Epigenetics-targeted drugs: current paradigms and future challenges. Signal Transduct Target Ther 9:332. https:\/\/doi.org\/10.1038\/s41392-024-02039-0","journal-title":"Signal Transduct Target Ther"},{"key":"5649_CR11","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2217\/14622416.9.12.1879","volume":"9","author":"P-K Lo","year":"2008","unstructured":"Lo P-K, Sukumar S (2008) Epigenomics and breast cancer. Pharmacogenomics 9:1879\u20131902. https:\/\/doi.org\/10.2217\/14622416.9.12.1879","journal-title":"Pharmacogenomics"},{"key":"5649_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116559","volume":"174","author":"L Trnkova","year":"2024","unstructured":"Trnkova L, Buocikova V, Mego M et al (2024) Epigenetic deregulation in breast cancer microenvironment: implications for tumor progression and therapeutic strategies. Biomed Pharmacother 174:116559. https:\/\/doi.org\/10.1016\/j.biopha.2024.116559","journal-title":"Biomed Pharmacother"},{"key":"5649_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02266-z","volume":"10","author":"J Song","year":"2025","unstructured":"Song J, Yang P, Chen C et al (2025) Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduct Target Ther 10:219. https:\/\/doi.org\/10.1038\/s41392-025-02266-z","journal-title":"Signal Transduct Target Ther"},{"key":"5649_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13072-024-00554-6","volume":"17","author":"R Prabhakaran","year":"2024","unstructured":"Prabhakaran R, Thamarai R, Sivasamy S et al (2024) Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy. Epigenetics Chromatin 17:31. https:\/\/doi.org\/10.1186\/s13072-024-00554-6","journal-title":"Epigenetics Chromatin"},{"key":"5649_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01525-9","volume":"15","author":"J Wei","year":"2024","unstructured":"Wei J, Wang X, Yu D et al (2024) MicroRNA-mediated autophagy and drug resistance in cancer: mechanisms and therapeutic strategies. Discov Oncol 15:662. https:\/\/doi.org\/10.1007\/s12672-024-01525-9","journal-title":"Discov Oncol"},{"key":"5649_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.semcancer.2019.02.003","volume":"58","author":"AA Farooqi","year":"2019","unstructured":"Farooqi AA, Fuentes-Mattei E, Fayyaz S et al (2019) Interplay between epigenetic abnormalities and deregulated expression of microRNAs in cancer. Semin Cancer Biol 58:47\u201355. https:\/\/doi.org\/10.1016\/j.semcancer.2019.02.003","journal-title":"Semin Cancer Biol"},{"key":"5649_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102922","author":"KMT Arif","year":"2020","unstructured":"Arif KMT, Elliott EK, Haupt LM, Griffiths LR (2020) Regulatory mechanisms of epigenetic miRNA relationships in human cancer and potential as therapeutic targets. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12102922","journal-title":"Cancers (Basel)"},{"key":"5649_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147350","author":"MJ Pajares","year":"2021","unstructured":"Pajares MJ, Alemany-Cosme E, Go\u00f1i S et al (2021) Epigenetic regulation of microRNAs in cancer: shortening the distance from bench to bedside. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22147350","journal-title":"Int J Mol Sci"},{"key":"5649_CR19","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.7150\/thno.11543","volume":"5","author":"G Bertoli","year":"2015","unstructured":"Bertoli G, Cava C, Castiglioni I (2015) MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. Theranostics 5:1122\u20131143. https:\/\/doi.org\/10.7150\/thno.11543","journal-title":"Theranostics"},{"key":"5649_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101214","author":"MM Rahman","year":"2019","unstructured":"Rahman MM, Brane AC, Tollefsbol TO (2019) MicroRNAs and epigenetics strategies to reverse breast cancer. Cells. https:\/\/doi.org\/10.3390\/cells8101214","journal-title":"Cells"},{"key":"5649_CR21","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20211812","author":"S Adhikari","year":"2022","unstructured":"Adhikari S, Bhattacharya A, Adhikary S et al (2022) The paradigm of drug resistance in cancer: an epigenetic perspective. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20211812","journal-title":"Biosci Rep"},{"key":"5649_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal2380","author":"WA Flavahan","year":"2017","unstructured":"Flavahan WA, Gaskell E, Bernstein BE (2017) Epigenetic plasticity and the hallmarks of cancer. Science. https:\/\/doi.org\/10.1126\/science.aal2380","journal-title":"Science"},{"key":"5649_CR23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2007.03.001","volume":"25","author":"K Yamane","year":"2007","unstructured":"Yamane K, Tateishi K, Klose RJ et al (2007) PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell 25:801\u2013812. https:\/\/doi.org\/10.1016\/j.molcel.2007.03.001","journal-title":"Mol Cell"},{"key":"5649_CR24","doi-asserted-by":"publisher","first-page":"7220","DOI":"10.1128\/MCB.00274-07","volume":"27","author":"AG Scibetta","year":"2007","unstructured":"Scibetta AG, Santangelo S, Coleman J et al (2007) Functional analysis of the transcription repressor PLU-1\/JARID1B. Mol Cell Biol 27:7220\u20137235. https:\/\/doi.org\/10.1128\/MCB.00274-07","journal-title":"Mol Cell Biol"},{"key":"5649_CR25","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3892\/ijo.2011.956","volume":"38","author":"S Catchpole","year":"2011","unstructured":"Catchpole S, Spencer-Dene B, Hall D et al (2011) PLU-1\/JARID1B\/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells. Int J Oncol 38:1267\u20131277. https:\/\/doi.org\/10.3892\/ijo.2011.956","journal-title":"Int J Oncol"},{"key":"5649_CR26","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.ccr.2014.04.024","volume":"25","author":"S Yamamoto","year":"2014","unstructured":"Yamamoto S, Wu Z, Russnes HG et al (2014) JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell 25:762\u2013777. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.024","journal-title":"Cancer Cell"},{"key":"5649_CR27","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1038\/s41388-018-0620-6","volume":"38","author":"G Paroni","year":"2019","unstructured":"Paroni G, Bolis M, Zanetti A et al (2019) HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases. Oncogene 38:2675\u20132689. https:\/\/doi.org\/10.1038\/s41388-018-0620-6","journal-title":"Oncogene"},{"key":"5649_CR28","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.4238\/2015.May.22.11","volume":"14","author":"LH Zhao","year":"2015","unstructured":"Zhao LH, Liu HG (2015) Immunohistochemical detection and clinicopathological significance of JARID1B\/KDM5B and P16 expression in invasive ductal carcinoma of the breast. Genet Mol Res 14:5417\u20135426. https:\/\/doi.org\/10.4238\/2015.May.22.11","journal-title":"Genet Mol Res"},{"key":"5649_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ncrna11060078","author":"IA Komporaly","year":"2025","unstructured":"Komporaly IA, Gheorghe AS, Kajanto LA et al (2025) MiRNA and its implications in the treatment resistance in breast cancer-narrative review of what do we know so far. Non-coding RNA. https:\/\/doi.org\/10.3390\/ncrna11060078","journal-title":"Non-coding RNA"},{"key":"5649_CR30","doi-asserted-by":"publisher","first-page":"101588","DOI":"10.1016\/j.bbrep.2023.101588","volume":"37","author":"TH Vo","year":"2024","unstructured":"Vo TH, El-Sherbieny Abdelaal E, Jordan E et al (2024) miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review. Biochem Biophys Rep 37:101588. https:\/\/doi.org\/10.1016\/j.bbrep.2023.101588","journal-title":"Biochem Biophys Rep"},{"key":"5649_CR31","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1158\/0008-5472.CAN-20-0505","volume":"80","author":"G Li","year":"2020","unstructured":"Li G, Kanagasabai T, Lu W et al (2020) KDM5B Is Essential for the Hyperactivation of PI3K\/AKT Signaling in Prostate Tumorigenesis. Cancer Res 80:4633\u20134643. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-0505","journal-title":"Cancer Res"},{"key":"5649_CR32","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s12967-024-05536-6","volume":"22","author":"G Wang","year":"2024","unstructured":"Wang G, Wu Y, Su Y et al (2024) TCF12-regulated GRB7 facilitates the HER2\u2009+\u2009breast cancer progression by activating Notch1 signaling pathway. J Transl Med 22:745. https:\/\/doi.org\/10.1186\/s12967-024-05536-6","journal-title":"J Transl Med"},{"key":"5649_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.55730\/1300-0152.2690","volume":"48","author":"S Noyan","year":"2024","unstructured":"Noyan S, G\u00fcr Dedeo\u011flu B (2024) miR-770-5p-induced cellular switch to sensitize trastuzumab resistant breast cancer cells targeting HER2\/EGFR\/IGF1R bidirectional crosstalk. Turk J Biol 48:153\u2013162. https:\/\/doi.org\/10.55730\/1300-0152.2690","journal-title":"Turk J Biol"},{"key":"5649_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215894","author":"S Noyan","year":"2019","unstructured":"Noyan S, Gurdal H, Dedeoglu BG (2019) Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0215894","journal-title":"PLoS One"},{"key":"5649_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.55730\/1300-0152.2655","volume":"47","author":"\u0130B Dolap\u00e7i","year":"2023","unstructured":"Dolap\u00e7i \u0130B, Noyan S, Polat AY et al (2023) miR-216b-5p promotes late apoptosis\/necroptosis in trastuzumab-resistant SK-BR-3 cells. Turk J Biol 47:199\u2013207. https:\/\/doi.org\/10.55730\/1300-0152.2655","journal-title":"Turk J Biol"},{"key":"5649_CR36","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z et al (2020) TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 48:W509\u2013W514. https:\/\/doi.org\/10.1093\/nar\/gkaa407","journal-title":"Nucleic Acids Res"},{"key":"5649_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baab007","author":"P J\u00e9z\u00e9quel","year":"2021","unstructured":"J\u00e9z\u00e9quel P, Gouraud W, Ben Azzouz F et al (2021) bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses. Database (Oxford). https:\/\/doi.org\/10.1093\/database\/baab007","journal-title":"Database (Oxford)"},{"key":"5649_CR38","doi-asserted-by":"publisher","first-page":"D1083","DOI":"10.1093\/nar\/gkaa968","volume":"49","author":"A Luna","year":"2021","unstructured":"Luna A, Elloumi F, Varma S et al (2021) CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics. Nucleic Acids Res 49:D1083\u2013D1093. https:\/\/doi.org\/10.1093\/nar\/gkaa968","journal-title":"Nucleic Acids Res"},{"key":"5649_CR39","doi-asserted-by":"publisher","first-page":"D380","DOI":"10.1093\/nar\/gkx1013","volume":"46","author":"H Han","year":"2018","unstructured":"Han H, Cho J-W, Lee S et al (2018) TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res 46:D380\u2013D386. https:\/\/doi.org\/10.1093\/nar\/gkx1013","journal-title":"Nucleic Acids Res"},{"key":"5649_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206239","volume":"13","author":"C Sticht","year":"2018","unstructured":"Sticht C, De La Torre C, Parveen A, Gretz N (2018) MiRWalk: an online resource for prediction of microRNA binding sites. PLoS One 13:e0206239. https:\/\/doi.org\/10.1371\/journal.pone.0206239","journal-title":"PLoS One"},{"key":"5649_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav1741","author":"SE McGeary","year":"2019","unstructured":"McGeary SE, Lin KS, Shi CY et al (2019) The biochemical basis of microRNA targeting efficacy. Science. https:\/\/doi.org\/10.1126\/science.aav1741","journal-title":"Science"},{"key":"5649_CR42","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1002\/ijc.32369","volume":"145","author":"JT Fekete","year":"2019","unstructured":"Fekete JT, Gy\u0151rffy B (2019) ROCplot.org: Validating predictive biomarkers of chemotherapy\/hormonal therapy\/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients. Int J cancer 145:3140\u20133151. https:\/\/doi.org\/10.1002\/ijc.32369","journal-title":"Int J cancer"},{"key":"5649_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/life11090868","author":"B Nami","year":"2021","unstructured":"Nami B, Ghanaeian A, Black C, Wang Z (2021) Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer. Life. https:\/\/doi.org\/10.3390\/life11090868","journal-title":"Life"},{"key":"5649_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2225","volume":"11","author":"JA Zell","year":"2009","unstructured":"Zell JA, Tsang WY, Taylor TH et al (2009) Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res 11:R9. https:\/\/doi.org\/10.1186\/bcr2225","journal-title":"Breast Cancer Res"},{"key":"5649_CR45","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni L (2017) HER2-positive breast cancer. Lancet (London England) 389:2415\u20132429. https:\/\/doi.org\/10.1016\/S0140-6736(16)32417-5","journal-title":"Lancet (London England)"},{"key":"5649_CR46","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","volume":"59","author":"F Schettini","year":"2021","unstructured":"Schettini F, Prat A (2021) Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast 59:339\u2013350. https:\/\/doi.org\/10.1016\/j.breast.2021.07.019","journal-title":"Breast"},{"key":"5649_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119360","author":"L Ma","year":"2023","unstructured":"Ma L, Li C, Yin H et al (2023) The mechanism of DNA methylation and miRNA in breast cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24119360","journal-title":"Int J Mol Sci"},{"key":"5649_CR48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13058-019-1160-x","volume":"21","author":"S Palomeras","year":"2019","unstructured":"Palomeras S, Diaz-Lagares \u00c1, Vi\u00f1as G et al (2019) Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer. Breast Cancer Res 21:79. https:\/\/doi.org\/10.1186\/s13058-019-1160-x","journal-title":"Breast Cancer Res"},{"key":"5649_CR49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ijc.22673","volume":"121","author":"A Barrett","year":"2007","unstructured":"Barrett A, Santangelo S, Tan K et al (2007) Breast cancer associated transcriptional repressor PLU-1\/JARID1B interacts directly with histone deacetylases. Int J Cancer 121:265\u2013275. https:\/\/doi.org\/10.1002\/ijc.22673","journal-title":"Int J Cancer"},{"key":"5649_CR50","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.semcancer.2018.11.001","volume":"57","author":"B Xhabija","year":"2019","unstructured":"Xhabija B, Kidder BL (2019) KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer. Semin Cancer Biol 57:79\u201385. https:\/\/doi.org\/10.1016\/j.semcancer.2018.11.001","journal-title":"Semin Cancer Biol"},{"key":"5649_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.23587","volume":"38","author":"Y Cao","year":"2024","unstructured":"Cao Y, Wu C, Ma L (2024) Lysine demethylase 5B (KDM5B): a key regulator of cancer drug resistance. J Biochem Mol Toxicol 38:e23587. https:\/\/doi.org\/10.1002\/jbt.23587","journal-title":"J Biochem Mol Toxicol"},{"key":"5649_CR52","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ccell.2018.10.014","volume":"34","author":"K Hinohara","year":"2018","unstructured":"Hinohara K, Wu H-J, Vigneau S et al (2018) KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance. Cancer Cell 34:939-953.e9. https:\/\/doi.org\/10.1016\/j.ccell.2018.10.014","journal-title":"Cancer Cell"},{"key":"5649_CR53","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1038\/s41388-022-02311-z","volume":"41","author":"R He","year":"2022","unstructured":"He R, Xhabija B, Gopi LK et al (2022) H3K4 demethylase KDM5B regulates cancer cell identity and epigenetic plasticity. Oncogene 41:2958\u20132972. https:\/\/doi.org\/10.1038\/s41388-022-02311-z","journal-title":"Oncogene"},{"key":"5649_CR54","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.4161\/cc.25142","volume":"12","author":"Z Enkhbaatar","year":"2013","unstructured":"Enkhbaatar Z, Terashima M, Oktyabri D et al (2013) KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. Cell Cycle 12:2100\u20132112. https:\/\/doi.org\/10.4161\/cc.25142","journal-title":"Cell Cycle"},{"key":"5649_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101525","volume":"298","author":"MP East","year":"2022","unstructured":"East MP, Johnson GL (2022) Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition. J Biol Chem 298:101525. https:\/\/doi.org\/10.1016\/j.jbc.2021.101525","journal-title":"J Biol Chem"},{"key":"5649_CR56","doi-asserted-by":"publisher","first-page":"297","DOI":"10.20517\/cdr.2018.11","volume":"2","author":"L Ponnusamy","year":"2019","unstructured":"Ponnusamy L, Mahalingaiah PKS, Chang Y-W, Singh KP (2019) Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer. Cancer drug Resist (Alhambra Calif) 2:297\u2013312. https:\/\/doi.org\/10.20517\/cdr.2018.11","journal-title":"Cancer drug Resist (Alhambra Calif)"},{"key":"5649_CR57","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12943-024-02011-0","volume":"23","author":"C-Y Li","year":"2024","unstructured":"Li C-Y, Wang W, Leung C-H et al (2024) KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges. Mol Cancer 23:109. https:\/\/doi.org\/10.1186\/s12943-024-02011-0","journal-title":"Mol Cancer"},{"key":"5649_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75557-0","volume":"14","author":"ES Tylden","year":"2024","unstructured":"Tylden ES, Delgado AB, Lukic M et al (2024) Roles of miR-20a-5p in breast cancer based on the clinical and multi-omic (CAMO) cohort and in vitro studies. Sci Rep 14:25022. https:\/\/doi.org\/10.1038\/s41598-024-75557-0","journal-title":"Sci Rep"},{"key":"5649_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1097491","volume":"14","author":"X Hu","year":"2023","unstructured":"Hu X, Yin G, Zhang Y et al (2023) Recent advances in the functional explorations of nuclear microRNAs. Front Immunol 14:1097491. https:\/\/doi.org\/10.3389\/fimmu.2023.1097491","journal-title":"Front Immunol"},{"key":"5649_CR60","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf800","author":"CR Hofman","year":"2025","unstructured":"Hofman CR, Hu J, Bryl R et al (2025) Nuclear argonaute:miRNA complexes recognize target sequences within chromatin-associated RNA and silence gene expression. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkaf800","journal-title":"Nucleic Acids Res"},{"key":"5649_CR61","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1039\/c5mb00513b","volume":"12","author":"H Denis","year":"2016","unstructured":"Denis H, Van Grembergen O, Delatte B et al (2016) MicroRNAs regulate KDM5 histone demethylases in breast cancer cells. Mol Biosyst 12:404\u2013413. https:\/\/doi.org\/10.1039\/c5mb00513b","journal-title":"Mol Biosyst"},{"key":"5649_CR62","doi-asserted-by":"publisher","first-page":"8980","DOI":"10.18632\/oncotarget.13858","volume":"8","author":"M Han","year":"2017","unstructured":"Han M, Xu W, Cheng P et al (2017) Histone demethylase lysine demethylase 5B in development and cancer. Oncotarget 8:8980\u20138991. https:\/\/doi.org\/10.18632\/oncotarget.13858","journal-title":"Oncotarget"},{"key":"5649_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114991","volume":"43","author":"B DiCiaccio","year":"2024","unstructured":"DiCiaccio B, Seehawer M, Li Z et al (2024) ZBTB7A is a modulator of KDM5-driven transcriptional networks in basal breast cancer. Cell Rep 43:114991. https:\/\/doi.org\/10.1016\/j.celrep.2024.114991","journal-title":"Cell Rep"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05649-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05649-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05649-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:02:47Z","timestamp":1791244967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-026-05649-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":63,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["5649"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05649-0","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human participants or animals. All experiments were performed using commercially available cell lines and reagents. Therefore, ethical approval was not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}